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Abstract
The Akt protein kinase, also known as protein kinase B, plays key roles in insulin receptor 
signalling and regulates cell growth, survival and metabolism. Recently, we described a 
mechanism to enhance Akt phosphorylation that restricts access of cellular phosphatases to the 
Akt activation loop (Thr308 in Akt1 or protein kinase B isoform alpha) in an ATP-dependent 
manner. In the present paper, we describe a distinct mechanism to control Thr308 
dephosphorylation and thus Akt deactivation that depends on intramolecular interactions of Akt C-
terminal sequences with its kinase domain. Modifications of amino acids surrounding the Akt1 C-
terminal mTORC2 (mammalian target of rapamycin complex 2) phosphorylation site (Ser473) 
increased phosphatase resistance of the phosphorylated activation loop (pThr308) and amplified 
Akt phosphorylation. Furthermore, the phosphatase-resistant Akt was refractory to ceramide-
dependent dephosphorylation and amplified insulin-dependent Thr308 phosphorylation in a 
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regulated fashion. Collectively, these results suggest that the Akt C-terminal hydrophobic groove 
is a target for the development of agents that enhance Akt phosphorylation by insulin.
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INTRODUCTION
The serine/threonine Akt protein kinases (Akt1, Akt2 and Akt3, also known as protein 
kinase B isoforms α, β and γ) affect multiple cellular functions related to cell growth and 
survival, differentiation, metabolism and migration [1,2]. Activation of Akt kinases is 
initiated by docking of the Akt pleckstrin homology (PH) domain to membrane 
phosphoinositide lipid products PtdIns(3,4,5)P3 or PtdIns(3,4)P2 [1,2]. Akt catalytic activity 
is further contingent on phosphorylation of two regulatory residues, one at its centrally 
located activation loop and one at the C-terminal tail. Complex mechanisms regulate the 
phosphorylation state of these two residues.
Akt activation loop phosphorylation (Thr308 in Akt1) is achieved by the phosphoinositide-
dependent kinase-1 (PDK1). The Akt C-terminal tail (Ser473 in Akt1) is phosphorylated by 
the mTORC2 (mammalian target of rapamycin complex 2) protein kinase, which is 
composed of the mammalian target of rapamycin catalytic subunit and the RICTOR 
(Rapamycin-insensitive companion of mTOR) subunit [3,4]. However, knockout of 
mTORC2 in mice only partially blocks Akt Ser473 phosphorylation, as evidenced in muscle 
tissues [5,6]. TANK-binding kinase 1 (TBK1) and atypical IκB kinase ε were found to 
phosphorylate Akt kinases at both the activation loop and the C-terminal tail [7,8]. 
Similarly, DNA-dependent protein kinase (DNA-PK) can phosphorylate the Akt1 C-
terminal tail (Ser473) during the DNA-damage response [9,10]. In addition, mTORC2 was 
found to phosphorylate additional residues in the extreme Akt1 C-terminus (Ser477 and 
Thr479) [11]. These sites are also phosphorylated by cyclin-dependent kinase 2 (Cdk2)/
cyclin A or by DNA-PK under synchronized cell cycle conditions and DNA-damaging 
conditions respectively.
Dephosphorylation of Akt kinases is accomplished by at least two phosphatases: the 
abundantly expressed protein phosphatase 2A (PP2A) [12,13] and PHLPP1/2 (PH domain 
leucine-rich repeat protein phosphatase). PHLPP1/2 is a member of the PP2C phosphatase 
family, which selectively dephosphorylates residues located in the C-terminal tails of protein 
kinase C (PKC) and of Akt kinases [14].
Previously, we showed that Akt dephosphorylation is subject to intrinsic allosteric control 
via ATP binding to Akt [15]. ATP binding alters the Akt activation loop conformation to 
enable interaction of the phosphorylated activation loop with other residues located in the 
kinase domain, including Arg273 (Arg274 in Akt2) resulting in steric hindrance of activation 
loop dephosphorylation. As a consequence, Akt activation at the plasma membrane is 
sustained or prolonged. This mechanism is probably responsible for the ‘paradoxical’ 
phosphorylation of Akt kinases observed during treatment of cells with several Akt-specific 
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ATP competitive inhibitors, including A-443654, GSK690693 and GDC-0068 [16–18]. In 
the case of Akt2, this mechanism has been shown to be biologically relevant. Specifically, 
Akt2 plays an important role in glucose metabolism and mitochondrial function [19,20] and 
the R274H mutation not only compromises the phosphatase-shielding cage but also is 
associated with severe insulin resistance and diabetes mellitus in humans [21]. Residues 
analogous to Arg274 also protect PKA (protein kinase A) and PKC kinases from 
dephosphorylation [22], suggesting that allosteric mechanisms controlling phosphatase 
access to regulatory residues can increase steady-state phosphorylation of Akt and other 
members of the protein kinase A, G, and C (AGC) group.
In the present paper, we characterize a second allosteric regulatory mechanism that controls 
Akt dephosphorylation kinetics and is mediated by intramolecular association of C-terminal 
sequences of Akt kinases with their kinase domains. We further provide evidence that the 
strength of interaction of C-terminal sequences with the kinase domain can be exploited to 
modulate Akt dephosphorylation kinetics. Molecular dials that gate phosphatase access are 
embedded in different parts of Akt kinase, including the nucleotide-binding pocket, the PH 
domain and the C-terminal sequences. The intricate interplay of these molecular dials is 
likely to contribute to insulin and ceramide signalling and they offer novel therapeutic 
targets to treat diseases ranging from cancer to diabetes.
MATERIALS AND METHODS
Plasmids, peptides and chemicals
Akt1 was fused at the N-terminus with an Src myristoylation signal (Myr, 
MGSSKSKPKSR) and at the C-terminus with a haemagglutinin (HA) epitope, as described 
in [15]. To distinguish heterologously expressed Akt from endogenous Akt, a 41-amino-acid 
large tag (LT), AIDGAGAGALVPRGSKET-AAAKFERQHMDSGAYPYDVPDYA, was 
fused at Akt C-terminus. The LT tag contained a peptide linker followed by a thrombin 
cleavage site, S-epitope tag and HA epitope tag. All plasmids were under the control of the 
cytomegalovirus promoter. Mutant constructs were generated using standard molecular 
biology strategies and confirmed by sequencing at the core facilities of Kimmel Cancer 
Center (Philadelphia, PA, U.S.A.). GFP in pFred143 (KH1035) was used in co-transfections 
to monitor transfection efficiency. H-89 {N-[2-(p-bromocinnamylamino)ethyl]-5-
isoquinolinesulfonamide}, a weak ATP-competitive Akt inhibitor (Km 2.5μM [23]) was 
purchased from LC Laboratories. The phosphatase inhibitor calyculin A was purchased Cell 
Signaling Technology. Pervanadate was prepared fresh by mixing equal molar amounts of 
hydrogen peroxide and NaVO4 [24].
Cell culture and transfection
H9C2 cells derived from rat neonatal hearts (A.T.C.C.) were cultured in M199 medium 
supplemented with 10% FBS and antibiotics. Human embryonic kidney (HEK) 293 cells 
were cultured in Dulbecco’s modified Eagle’s essential medium (DMEM) supplemented 
with 10% FBS and antibiotics. Primary human airway smooth muscle cultures were 
generated as described previously [25]. Cells were transfected using Fugene-6 HD (Roche) 
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or Lipofectamine 3000 Reagent (Life Technologies) according to the manufacturer’s 
protocols.
Cell extract Akt dephosphorylation
To maximally phosphorylate Akt1 constructs at the activation loop (Thr308), Akt constructs 
were co-transfected with PDK1. Transfected cells were stimulated for 15 min with 2 μM 
insulin, in the presence of the tyrosine phosphatase inhibitor pervanadate (100 μM). To 
harvest, stimulated cells were washed once with ice-cold PBS before they were placed in a 
cell culture dish on an ethanol/solid-CO2 bath to flash freeze. Cell-free extracts were 
prepared by scraping flash-frozen cells into phosphatase assay buffer (50 mM Hepes, pH 
7.5, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM NaF, 5 μM H-89 ATP-competitive 
inhibitor and 0.1% NP40 detergent supplemented with 5 μg/ml leupeptin, 5 μg/ml aprotinin, 
10 mM PMSF and 1 mM DTT). H-89 was used in the cell-free system as an ATP-
competitive inhibitor against Akt (Km for Akt = 2.5 μM [23]). Total cell-free extracts were 
incubated at 30°C to initiate dephosphorylation. At the indicated times, a fixed amount of 
cell extract was removed from incubation and the reaction stopped by adding an equal 
volume of stop assay buffer (25 mM Tris/HCl, pH 7.6, 137 mM NaCl, 10% glycerol, 1% 
NP40, 10 mM NaF supplemented with 5 μg/ml leupeptin, 5 μg/ml aprotinin, 10 mM PMSF, 
1 mM NaVO4 and 100 nM calyculin, 20 mM β -glycerolphosphate and 1 mM sodium 
pyrophosphate). After lysis on ice for 10 min, cell lysates were clarified, reduced and 
denatured by PAGE sample buffer for immunoblotting.
Recombinant Akt and protein kinase A dephosphorylation
Recombinant activated Akt1 (50 ng, Millipore) and recombinant activated PKA catalytic 
subunit (50 ng, New England Biolabs) was dephosphorylated in 50 μl of optimized 
phosphatase assay buffer containing non-ionic detergents and supplemented with metal ions 
(1 mM MnCl2 or 5 mM MgCl2) and phospholipid micelles containing 4 μM PtdIns(3,4,5)P3, 
40 μM phosphoserine and 40 μM phosphocholine (Echelon Biosciences or Avanti Polar 
Lipids). The assays were initiated by adding 60–70 ng of recombinant PP2A catalytic 
subunit (L309 deletion, Cayman Chemicals) or 40 units of λ-phosphatase (Cell Signaling 
Technology).
Phosphatase assay with p-nitrophenyl phosphate as substrate
The same conditions used for Akt dephosphorylation were applied to assays using the 
colorimetric p-nitrophenyl phosphate phosphatase (PNPP) substrate. Assays were set up in 
untreated 96-well plates (Nunc 80040LE 0910) on ice and warmed at 37°C for 2 min before 
adding 50 μl of commercially prepared PNPP substrate (Anaspec). Phosphatase activity was 
measured at 405 nm from 5 to 60 min after incubation at 37°C. Where indicated, 200 ng of 
PP2A and 40 units of λ-phosphatase were used.
Immunoblotting
Akt phosphorylation (Ser473 and Thr308) was measured as described previously [26]. 
Briefly, cells were homogenized on ice using a NP40 lysis buffer (25 mM Tris/HCl, pH 7.6, 
137 mM NaCl, 10% glycerol, 1% NP40 and 10 mM NaF) freshly supplemented with 1 mM 
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sodium pyrophosphate, 5 μg/ml leupeptin, 5 μg/ml aprotinin, 1 mM EDTA, 10 mM PMSF, 1 
mM NaVO4 and 1 mM DTT. Clarified cellular lysates were boiled and separated by SDS/
PAGE (4–12% gels) and transferred on to nitrocellulose membranes. For immunoblotting, 
membranes were blocked for 30 min with Li-Cor blocking buffer and probed with 
antibodies at 4°C overnight. The blots were subsequently incubated with either IRDye 700 
or 800 secondary antibodies conjugated to IR fluorophores for 60 min. Bands were 
visualized and directly quantified using the Odyssey Infrared Imaging System (Li-Cor). The 
following antibodies were used at 1:1000 dilution: anti-phospho-proline-rich Akt substrate 
of 40 kDa (PRAS40) Ser246, anti-phosph-ERK1/2 (extracellular-signal-regulated kinase 
1/2), anti-phospho-Akt (Thr308), anti-phospho-Akt (Ser473; from Cell Signaling 
Technology), anti-total Akt (from BD Biosciences) and anti-GAPDH (glyceraldehyde-3-
phosphate dehydrogenase; from Santa Cruz Biotechnology) and anti-HA (from Covance).
Modelling structure
Structural figures were prepared using PyMOL (http://www.pymol.org) based on structures 
of activated Akt2 kinase domain with adenosine 5′-[β, γ-imido]triphosphate (AMP-
PNP)/Mn2+ [27,28] and PKA [29].
Calculation of relative free energy contributions
A CHARMM (Chemistry at HARvard Macromolecular Mechanics)-based method [30] was 
utilized to approximate the free energy contribution of each PDK1-interacting fragment 
(PIFtide) residue side chain interaction with the kinase domain-binding groove interface. 
The free energy contributions of the side chains are approximated by first removing peptide 
backbone atoms, transforming the α-carbon into a methyl group and calculating the linear 
interaction energy (LIE) difference between the scaled potential energies of the bound and 
free states [30]. Calculations are performed utilizing the Generalized-Born with Molecular 
Volume (GBMV) implicit solvent model providing a rigorous treatment of desolvation 
penalties.
Statistical analysis
A commercial software package was used for statistical analysis (Graph Pad Software). 
Comparison of means ± S.E.M. was analysed by non-parametric Mann–Whitney test.
RESULTS
Two AGC kinases, Akt and PKA, exhibit differential phosphatase sensitivity
When Akt kinases are ATP-bound, their phosphorylated activation loop (pThr308 in Akt1) 
interacts with other residues, His194 and Arg273, within the kinase domain and this 
interaction restricts cellular phosphatases from accessing the phosphorylated site [15]. The 
amino acid residues required for constructing this ‘phosphatase-shielding cage’ are 
conserved among AGC kinases, including PKA [22] (Figure 1A). However, unlike Akt 
kinase, inactive (regulatory subunit-bound) PKA is constitutively phosphorylated at the 
activation loop via the combined abilities of auto-phosphorylation and phosphatase 
resistance [31]. PKA activation loop is phosphorylated by PKA itself or by PDK1. In 
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addition, importantly, the fully phosphorylated PKA catalytic subunit becomes highly 
resistant to phosphatases in cells and in cell-free assays [32–34].
To directly compare dephosphorylation sensitivity between Akt and PKA using cell-free 
conditions, H9C2 cell extracts were prepared containing either constitutively phosphorylated 
Akt1 (Myr-Akt1) or constitutively phosphorylated PKA, using a rapid solid-CO2 freezing/
protein extraction method [15]. Incubation of cell extracts at 30°C resulted in 85% of Myr-
Akt1 being dephosphorylated by cellular phosphatases within 90 min; inclusion of the 
phosphatase inhibitor calyculin A inhibited this dephosphorylation (Figure 1B). By contrast 
and as expected, only 7% of PKA was dephosphorylated following incubation at 30°C for 
90 min. It is worth mentioning that transfected Myr-Akt1 expression was much higher than 
endogenous Akt, but transfection did not affect endogenous Akt response (Supplementary 
Figure S1).
To rule out the possibility that PKA dephosphorylation resistance was caused either by 
unknown factors in the cellular milieu or by intramolecular interactions between the PKA 
catalytic subunit and its regulatory subunit [35], we measured in vitro dephosphorylation 
using recombinant preparations of Akt and PKA catalytic subunits. When (pre)-
phosphorylated recombinant Akt1 or PKA (50 ng each) were incubated with the PP2A 
catalytic subunit (50 ng), 84% of Akt Thr308 was dephosphorylated within 60 min, yet only 
20% of PKA pThr197 was dephosphorylated (Figure 1C). PKA also resisted 
dephosphorylation more efficiently than did Akt1 when incubated with the pan-substrate 
bacteriophage λ phosphatase (Figure 1C, second panel). Thus, purified Akt kinase is 
‘intrinsically’ sensitive to dephosphorylation, whereas PKA is ‘constitutively’ phosphatase-
resistant.
Replacing Akt C-terminus with PIFtide enhances Akt activation loop phosphorylation
As noted earlier, PKA and Akt isoforms are members of AGC kinase family and, as shown 
for Akt1 and Akt2, their catalytic domains share a high degree of structural and amino acid 
homology, except at their C-termini (Figure 2A). An active Akt1 structure is not available. 
We compared the PKA C-terminus to active Akt2 structure with the S474D peptide (PDB 
code 1o6k). Since most of our biochemical studies were performed with Akt1, we indicated 
the corresponding Akt1 amino acid residues for clarity.
Structural comparison shows marked differences in intramolecular interactions formed by 
the respective C-termini. The PKA C-terminus is well-ordered, prior to the FxxF motif 
(residues 334–344). By comparison, the Akt C-terminus is disordered prior to the FxxF 
motif (residues 450–455). Using crystal structures of PKA (PDB code 4dg0) and Akt2 (PDB 
code 1o6k), a CHARMM-based method enabled us to approximate the free energy 
contribution of each C-terminal residue’s side chain interaction with the kinase domain-
binding groove interface (Supplementary Table S1). This analysis reveals that PKA Phe350 
of the FxxF motif is involved in several buried electrostatic interactions with residues Gln35, 
Lys92 and Lys111; consequently, the PKA Phe350 interaction within the kinase domain fold 
is −0.7 kcal/mol more favourable when compared with the comparable Akt residue (Akt2 
Phe473) interactions. These ‘high contact order’ interactions are particularly stabilizing to 
tertiary structures [36].
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Thus structural analysis predicts that PKA C-terminus forms strong intramolecular 
interactions involving the FxxF motif. By contrast, the Akt2 C-terminus interacts with the 
kinase domain in a more labile and dynamic fashion. This view is supported by experimental 
data revealing weak binding of the Akt C-terminus to the kinase domain [37]. The binding 
affinity of wild-type (WT) Akt C-terminal peptide for the hydrophobic groove on the kinase 
N-lobe is greater than 5000 μM. Even with phosphomimetic S473D replacement, the C-
terminal peptide affinity remains at 3600 μM [37].
We tested phosphatase sensitivity of phospho-Akt in cells by deletion of the PH domain 
(ΔPH-Akt1), which constitutively localizes Akt in the cytosol. Treating ΔPH-Akt1 
expressing cells with a phosphatase inhibitor (calyculin A) restored phosphorylation (Figure 
2B), indicating that phosphatase inhibition enhances cytosolic Akt phosphorylation. 
Transfected ΔPH-Akt1-WT expression was much higher than endogenous Akt 
(Supplementary Figure S2A).
We next tested the hypothesis that the differences in the strength of the intramolecular 
interactions of C-terminus FxxF motif may affect the phosphatase protection of activation 
loop (Akt pThr308). Unlike peptide sequences that correspond to WT Akt C-terminus which 
has weak affinity (~5000 μM) for binding the Akt kinase domain, a peptide derived from the 
C-terminus of PKC-related protein kinase 2 (PRK2) (PIFtide) binds Akt at 6 μM [37] 
(Figure 2C). Thus, we replaced the WT Akt C-terminus with the high-affinity PIF peptide 
(ΔPH-Akt1-PIF, SEEEQEMFRDFDYIADWC). When expressed in HEK293 cells, the 
ΔPH-Akt1-PIF construct enhanced Thr308 activation loop phosphorylation to an extent 
comparable to that observed with membrane-bound Myr-ΔPH-Akt1 (Figure 2D). The 
expression level of ΔPH-Akt1 mutants was much higher than that of endogenous Akt, but 
their phosphorylation was not affected by insulin stimulation (Supplementary Figure S2B). 
Interestingly, phosphomimetic mutations in ΔPH-Akt1 (S473D) or in ΔPH-Akt2 (S474D) 
failed to enhance Thr308 phosphorylation, probably due to weak ligand affinity even after 
S473D mutation [37] (Figure 2D; Supplementary Figure S2C).
Previously we demonstrated that ATP-binding site occupancy imparts dephosphorylation 
resistance to Akt [15]. To test whether the enhanced phosphatase resistance in ΔPH-Akt1-
PIF depends on occupation of the ATP-binding pocket, we mutated the ATP-binding lysine 
residue (Lys179 in the full-length human Akt1) to methionine (K179M) in ΔPH-Akt1-PIF. 
This construct (K179M-ΔPH-Akt1-PIF) was poorly phosphorylated at Thr308, yet 
phosphorylation was restored when cells were treated with calyculin A with or without 
insulin (Figure 2E; Supplementary Figure S2D). Thus, the phosphatase resistance in ΔPH-
Akt1-PIF is contingent upon occupation of the ATP-binding pocket previously shown to 
support Akt dephosphorylation resistance.
Replacing the Akt C-terminus with PIFtide blocks Akt dephosphorylation in cell-free 
assays
To avoid confounding variables inherent in cell-based studies [38,39], we used cell-free 
assays to directly test the ability of PIFtide to block phosphatase access to the Akt Thr308 
site.
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To differentiate transfected full-length Akt from endogenous Akt, we fused full-length 
Akt1-cDNA with a 41-amino-acid LT. This epitope tag consisted of a flexible linker, a 
thrombin cleavage site, an S-tag and a HA-tag (Figure 3A). To facilitate Akt 
dephosphorylation kinetics monitoring in the cell-free assay, we first established conditions 
that maximally phosphorylated Thr308 in Akt1-LT WT.
We tested cell treatment conditions in H9C2 cells and showed that combining PDK1 
expression with insulin and pervanadate treatment resulted in maximal Thr308 
phosphorylation of the Akt1-LT WT construct (Figure 3A). Insulin/pervanadate/PDK1 
treatment resulted in Akt1-LT WT phosphorylation at a level comparable to that observed 
for myristoylated Akt (Figure 3A) and for PIFtide-fused Akt1 (Figure 3B). PDK1/insulin/
pervanadate treatment also maximized Akt1-LT WT phosphorylation in HEK293 cells 
(Supplementary Figure S3A).
To test Akt dephosphorylation kinetics in cell-free extracts, H9C2 cells expressing 
maximally phosphorylated Akt1-LT WT and Akt1-LT PIF were snap-frozen using an 
ethanol/solid CO2 bath. Cell extracts were prepared with an EDTA-detergent extraction 
buffer without phosphatase inhibitors at 4°C. Akt1-LT WT was dephosphorylated by 89 ± 
2% within 30 min of incubation at 30°C (Figure 3B). Under the same conditions, Akt with 
the PIFtide was only dephosphorylated by 48±2% (P < 0.01), suggesting that PIFtide 
replacement enhanced Akt resistance to phosphatase activity. Unlike transfected constructs, 
endogenous Akt was similarly dephosphorylated in different cell extract types 
(Supplementary Figure S3B).
To directly assess whether PIFtide blocks Akt1 dephosphorylation, we incubated the 
purified PP2A catalytic subunit with recombinant phospho-Akt1 in a solution containing 
sonicated lipid micelles and PIFtide (Figure 3C). Under these conditions, PIFtide blocked 
Akt dephosphorylation by PP2A. For a control, we performed dephosphorylation assays in 
the absence of peptides and also with control peptides (Akt2 S473D C-terminal peptide, α-
helical region of Akt peptide, the myristoylated Src peptide and the myristoylated PKA 
peptide). With the exception of PIFtide, none of the peptides tested affected Akt 
dephosphorylation significantly (Figure 3C; Supplementary Figure S3C).
To rule out the possibility that PIFtide peptide directly inhibited phosphatases, we 
determined the effect of PIFtide on dephosphorylation of a universal phosphatase substrate, 
PNPP. Under conditions identical with those used in the Akt dephosphorylation assay, 
PIFtide did not affect the ability of PP2A to process PNPP (Figure S3D). Collectively, these 
data suggest that the Akt C-terminal interaction with PIFtide renders Akt resistant to 
phosphatase-mediated dephosphorylation.
C-terminal Akt residues can be modified to progressively decrease Akt dephosphorylation
We show the superposition of the C-terminal PIFtide (PDB code 1o6l) and S474D peptide 
(PDB code 1o6k) in the active Akt2 isoform in Figure 4A. C-terminal sequences 
surrounding phosphorylation sites of Akt1 (Ser473) and Akt2 (Ser474) are highly 
homologous (Figure 2A).
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In contrast with the serine/isoleucine motif in the Akt C-terminus, PIFtide contains a 
charged aspartic acid residue and a bulky tryptophan residue. We hypothesized that these 
two residues will enhance dephosphorylation protection in Akt kinases. To test this 
hypothesis, we sequentially replaced Akt1 amino acids in the tail with the corresponding 
PIFtide amino acids (Figure 4B). Cells expressing these mutants in the ΔPH-Akt1-S473D 
background revealed that combined S477D/G478W replacement alone enhanced steady-
state Thr308 phosphorylation approximately 7-fold (Figure 4B).
We noted that ‘DW’ dipeptide replacement alone was still much less effective than the 
native PIFtide (Figure 4B), suggesting that additional changes surrounding the FxxF motif 
(HFPQF as compared to MFRDF) contribute to dephosphorylation protection. Sequential 
replacement of these residues revealed that adding Q471D to S473D/S477D/G478W 
(DDDW) further increased phosphorylation from 6.6-fold to more than 17-fold (Figure 4B). 
Expression level of ΔPH-Akt1 mutants was much higher than that of endogenous Akt, but 
their phosphorylation were not affected by insulin stimulation (Supplementary Figure S2B). 
Taken together these results suggest that C-terminal sequences can be progressively 
modified to restrain phosphorylated Thr308 from cellular phosphatases, thereby increasing 
activation loop Akt phosphorylation and kinase activity.
A modified Akt C-terminus enhances insulin responsiveness
The preceding C-terminal modifications were tested in an Akt fragment lacking the PH 
domain, which does not respond to insulin stimulation [1]. To test the effects of C-terminal 
modification on insulin responses, we introduced the DDW (S473D/S477D/G478W) and 
DDDW (Q471D/S473D/S477D/G478W) mutations into full-length Akt containing the PH 
domain (Figure 5A). C-terminally modified Akt1 constructs were fused with a 41-amino-
acid LT to differentiate transfected Akt1 mutants from endogenous Akt. After transfecting 
these constructs into H9C2 cells, both DDW-and DDDW-modified Akt1-LT constructs 
demonstrated amplified insulin-dependent Thr308 phosphorylation (Figure 5B). Whereas 
WT Akt1 and the DDW-modified Akt1 responded similarly at acute insulin stimulation, 
only the DDW-modified Akt1 could sustain insulin-dependent phosphorylation at 4 h after 
insulin stimulation (Figure 5C).
Myr of Akt kinase, found in the viral Akt oncogene [40], causes constitutive activation loop 
phosphorylation that is refractory to serum starvation and phosphoinositide-3-kinase (PI3K) 
inhibitor treatment [1] (Figure 3A). In the presence of insulin, the specific phosphorylation 
of the Akt1-LT-DDDW mutant approached that of Myr-Akt1 (Figure 5D). Yet, unlike Myr-
Akt1, Akt1-LT-DDDW phosphorylation was reduced 8-fold within 60 min of insulin 
removal. Thus, C-terminal peptide mimics do not induce constitutive Akt 
hyperphosphorylation, but rather increase the transient response to insulin.
Next we tested phosphatase resistance of DDDW-modified Akt1-LT in the cell-free 
dephosphorylation assay. Insulin/pervanadate/PDK1 treatment maximal phosphorylated WT 
Akt to a level comparable to that of DDDW-modified Akt1-LT. Cell extracts were prepared 
after rapid freezing. To ensure a lack of protein kinase activity in the extracts, EDTA was 
included. Upon further incubation of cell extracts at 30°C, 90% of WT Akt1 was 
dephosphorylated within 30 min. In contrast, only 56% of DDDW-Akt1-LT was 
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dephosphorylated (Figure 5E). Furthermore, DDDW modification provided Thr308 
dephosphorylation resistance similar to that caused by full-length PIFtide replacement 
(Figure 3B; Supplementary Figure S4). Unlike transfected constructs, endogenous Akt were 
similarly dephosphorylated in different cell extract types (Supplementary Figure S3B). 
Thus, DDDW modification enables the Akt Thr308 site to resist cellular phosphatases.
Modified Akt kinase C-terminus renders Akt resistant to C2-ceramide inhibition
Akt kinases link insulin and other growth factors to increased cell growth, metabolism and 
survival [41–43]. Insulin resistance is associated with induction of the sphingolipid second 
messenger ceramide and ceramide directly regulates apoptosis susceptibility through 
inhibition of Akt [44,45]. Indeed, treatment of H9C2 myoblast cells and primary human 
airway smooth muscle cells for 2 h with 100 μM soluble short-chain ceramide (C2-
ceramide) reduced insulin-stimulated endogenous Akt phosphorylation by 90%(Figure 6A).
To test whether C-terminally modified phosphatase-resistant Akt constructs resist C2-
ceramide inhibition, we transfected DDDW-modified constructs into H9C2 cells and treated 
the cells with C2-ceramide. DDDW-modified ΔPH-Akt1 and full-length Akt1-LT remained 
highly phosphorylated at Thr308 after C2-ceramide treatment (Figures 6B and 6C). 
Consistently, Akt1-LT-DDDW also enhanced phosphorylation of the Akt substrate 
phospho-PRAS40 under C2-ceramide treatment conditions in both primary human airway 
smooth muscle cells (Figure 6D) and H9C2 cells (Supplementary Figure S5B). Interestingly, 
in the absence of ceramide, insulin-stimulated pPRAS40 phosphorylation was not further 
augmented by Akt1-LT-DDDW expression (Supplementary Figures S5A and S5B). These 
data suggest that targeting Akt dephosphorylation resistance could potentially protect cells 
from ceramide-mediated insulin resistance.
DISCUSSION
Activation loop phosphorylation is an essential prerequisite for catalytic activity of most 
AGC kinases [46,47]. In the present study, we demonstrate that the C-terminal signature 
hydrophobic motifs (FxxF) of the two AGC kinases Akt (protein kinase B) and PKA 
increase activation loop phosphorylation by restricting access of cellular phosphatases to this 
site. Whereas C-terminus-dependent dephosphorylation resistance of PKA is constitutive, 
dephosphorylation resistance of the Akt activation loop is conditional as it depends on 
membrane-proximal localization and on ATP binding to Akt (Figure 7).
Previous work showed that the Akt C-terminal hydrophobic motif binds Akt with low 
affinity, even when the regulatory site (Ser473 in Akt1) is phosphorylated [37]. Low-affinity 
interaction of the Akt C-terminus with the kinase domain is further supported by structural 
data revealing an inactive ‘open’ conformation with a disordered αC-helix and disordered 
C-terminal tail [28,37]. By contrast, the C-terminus of PKA (PDB codes 4dg0 and 4dg2) 
forms high-affinity electrostatic interactions with N-terminal residues (Ser34/Gln35) that 
should confer significant conformational rigidity on this region; these residues are not 
conserved in Akt kinases [29]. As shown in the present study, increasing the strength of 
interaction of C-terminal sequence variants with the kinase domain renders the Akt 
activation loop resistant to dephosphorylation independent of intracellular localization.
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Akt conformational change induced by membrane binding coordinately regulates the 
phosphorylation of both the activation loop and the C-terminus [1,4]. However, these two 
sites are phosphorylated by distinct protein kinases (PDK1 and mTORC2). Whereas 
abolishing activation loop phosphorylation (via PDK1 deletion) does not affect C-terminal 
phosphorylation in embryonic stem cells [48], abolishing C-terminal phosphorylation blunts 
activation loop phosphorylation in a cell-type/condition-dependent manner.
Our research group, as well as other research groups [49], has found that mutating Ser473 to 
alanine in membrane-bound Akt reduced activation loop phosphorylation by nearly 95% 
(Supplementary Figure 6B). Similarly, abolishing Ser473 phosphorylation via genetic 
mTORC2 inhibition (RICTOR subunit deletion or knockdown) blunts activation loop 
phosphorylation in PTEN (phosphatase and tensin homolog)-deleted mouse prostate glands 
[50] and in several human cancer cells [3]. These results suggest that lack of Ser473 
phosphorylation increases Akt phosphatase sensitivity leading to reduced Thr308 
phosphorylation in these cells.
Surprisingly, Ser473 phosphorylation can be uncoupled from Thr308 phosphorylation. 
Abolishing Akt C-terminal phosphorylation in primary mouse embryonic fibroblast cells 
fails to reduce Thr308 phosphorylation [5,50–52]. Also, reducing mTORC2 activity blocked 
both Ser473 and Thr308 phosphorylation in insulin-stimulated 3T3-L1 adipocytes [53], but in 
brown adipocyte precursor cells, it only blocked Ser473 phosphorylation [54]. It is likely that 
mouse embryo fibroblasts and brown adipocyte precursor cells possess specific factors that 
enhance phosphatase resistance even in the absence of Akt C-terminal phosphorylation.
Phosphorylation of the Akt C-terminus regulates catalytic activity [47,55] and substrate 
selectivity of this kinase [56,57]. As shown in the present study by use of phosphomimetic 
mutants, phosphorylation of the C-terminus of Akt1 at Ser473 is required but not sufficient 
for conferring dephosphorylation resistance on the activation loop. The abundantly 
expressed phosphatase PP2A is the primary phosphatase to dephosphorylate Akt kinases 
(both the activation loop Thr308 site and the C-terminal Ser473 site) [12,13,58–60]. In 
addition, the Akt C-terminal site could also be dephosphorylated by a member of the PP2C 
phosphatase family, PHLPP1/2 [61,62] and by protein phosphatase-1 [63]. Consistently, our 
earlier study showed that both Thr308 and Ser473 sites can render phosphatase resistant by 
ATP binding in the presence of recombinant PP2A (Supplementary Figure in [15]). 
Furthermore, ceramide treatment blocked the phosphorylation at both Thr308 and Ser473 
sites (Supplementary Figure S6). Thus, we suggest that one function for Ser473 
phosphorylation is to enhance phosphatase resistance at the activation loop. 
Dephosphorylation kinetics probably affects multiple functions of Akt kinases including 
insulin-mediated and Akt-dependent modulation of glucose and lipid metabolism [41,43,64]. 
After insulin stimulation, the Akt2 isoform not only binds phosphoinositide lipids, but is 
recruited into a GLUT4 (glucose transporter type 4)-containing raft membrane containing 
potential regulatory proteins such as Cbl (Casitas B-lineage Lymphoma), Crk adapter 
molecule, flotillin and TC10 (also known as Rho-related GTP-binding protein Q) [65].
Insulin resistance, as observed in diabetes, is associated with reduced Akt activity and up-
regulation of the sphingolipid second messenger ceramide [44,45]. Ceramide is known to 
Chan et al. Page 11
Biochem J. Author manuscript; available in PMC 2015 December 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
modestly enhance PP2A activity (~1.5–2-fold) [66], but direct phosphatase activation by 
ceramide is not the main mechanism for Akt phosphorylation blockade. Instead, ceramide 
blocks the translocation of the Akt PH domain to the plasma membrane [67,68] via 
interaction with and/or phosphorylation by PKCζ and membrane rafts [69–72]. Thus, 
ceramide does not block phosphorylation in ΔPH-Akt constructs.
Along with other research groups, we have shown that the deletion of the Akt PH domain 
prevents Akt translocation to the plasma membrane [1]. Consequently, expressed ΔPH-
Akt1-WT does not respond to growth factor stimulation and is essentially unphosphorylated 
when expressed in HEK293 cells (Supplementary Figure S2A) and in many other cell types 
[73–77]. But treating cells with the phosphatase inhibitor calyculin A was sufficient to 
restore Thr308 phosphorylation in ΔPH-Akt1-WT over 200-fold (Supplementary Figure 
S2A). Thus, ΔPH-Akt1-WT is already dephosphorylated in the absence of ceramide 
treatment.
Our earlier studies showed that membrane-localized Akt becomes more phosphatase 
resistant [15]. Also, ceramide blocked Thr308 phosphorylation in WT Akt in the presence of 
insulin stimulation (Figure 6C) by preventing the translocation of Akt to the plasma 
membrane [67,68]. Thus, DDDW-modified Akt1 resisted ceramide treatment by enhancing 
phosphatase resistance even when not membrane-bound. We show in the present study that 
a modified Akt C-terminus not only increases steady-state Akt phosphorylation upon insulin 
exposure, but also imparts resistance to ceramide-dependent Akt dephosphorylation leading 
to robust Akt1 downstream signalling. These results suggest novel approaches to protect 
cells against ceramide-associated cytotoxic effects.
Finally, removal of insulin triggers dephosphorylation of C-terminally modified Akt. The 
insulin-responsive enhancement of Akt phosphorylation is distinct from constitutive 
phosphorylation as observed in membrane-targeted myristoylated Akt (which confers 
oncogenic properties) [1,78,79]. Thus, the requirement of physiological insulin to enhance 
C-terminally modified Akt phosphorylation suggests that Akt agonists based on modified 
Akt C-termini can be developed that have favourable pharmacological properties and are not 
encumbered by oncogenic risks.
Akt translocation to the plasma membrane promotes both its phosphorylation and its 
phosphatase resistance to sustain Akt activity. In addition, other cell membrane 
compartments, such as mitochondria-associated endoplasmic reticulum and the nucleus, also 
contain Akt substrates that affect Akt function. For example, Sasaki et al. [80] used 
subcellular-targeted fluorescent Akt substrate reporter to show that Akt phosphorylation 
occurs at Golgi and mitochondria subcellular membrane compartments, but not within 
cytosol. Also, we and others [4] have shown cytosolic Akt is readily dephosphorylated 
(Figure 2B).
The mechanism for activating Akt in these subcellular compartments is unclear. One 
possibility is that phosphorylated Akt traverses from the plasma membrane via D3-
phosphoinositide-containing membrane vesicles that support Akt phosphorylation and/or 
phosphatase protection. Alternatively, components of Akt signalling pathway may already 
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reside at these subcellular locations. Specifically, Akt kinase, PI3K, D3-phosphoinositides, 
PDK1 and mTORC2 have been found in the nucleus [81], at mitochondria-associated 
endoplasmic reticulum membranes [81–85] and at ClipR-59 lipid/raft associated scaffolding 
protein in adipocytes [86,87].
In summary, our results demonstrate that differences in dephosphorylation resistance among 
AGC kinases can be explained in part by differences in the affinity of intramolecular 
interactions between the C-termini and the kinase domains. Specifically, higher-affinity 
interactions between these functional domains confer higher degrees of phosphorylation 
resistance. These findings provide a rational basis for the development of C-terminal 
peptidomimetics for therapeutic purposes.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Constitutive dephosphorylation resistance of phospho-PKA, but not phospho-Akt, in a 
cell-free assay
(A) Superimposition of Akt kinase domain (Akt2–Mn–AMP-PNP–G–SK3, green, PDB 
code 1o6k [28]) and PKA kinase domain (PKA–Mn–ATP–PKI, brown, PDB code 1cdk 
[88]). In the presence of bound ATP analogues, the phosphorylated activation loops (Thr308 
in Akt1, Thr197 in PKA) shown are stabilized by invariable histidine (His194 in Akt1, His87 
in PKA) and arginine (Arg273 in Akt1, Arg165 in PKA) residues. The structure was modelled 
on active human Akt2 crystal structures bound to the ATP analogue AMP-PNP and Mn2 + 
(PDB code 1o6k). Since most of our biochemical studies were performed with Akt1, we 
indicate the corresponding Akt1 amino acid residues in the structure for clarity. (B) Cell 
extract dephosphorylation of Akt and PKA. H9C2 cells expressing constitutively 
phosphorylated Myr-Akt1-HA and phosphorylated endogenous PKA were flash-frozen and 
extracted on ice. Aliquots of cell extracts without phosphatase inhibitors were incubated at 
30°C for 90 min. After incubation, protein extracts were subjected to immunoblot analysis 
using antibodies detecting phosphorylated Akt (Thr308), HA-tagged Akt, phosphorylated 
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PKA (Thr197) and total PKA. (C) Recombinant phospho-PKA catalytic subunit, but not that 
of recombinant phospho-Akt, resists dephosphorylation. Recombinant Akt1 and PKA (50 
ng) were incubated with PP2A (70 ng of PP2A-C) or pan-substrate bacteriophage λ 
phosphatase (40 units) for 60 min at 30°C. Images show Akt1 Thr308 phosphorylation, total 
Akt, PKA Thr197 phosphorylation and total PKA. The histograms show the percentage of 
pThr308 or pThr197 dephosphorylation. n=4/group. *P < 0.05 compared with PKA 
dephosphorylation by PP2A.
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Figure 2. Replacing cytosolic Akt1 C-terminal sequences with PIFtide 
(SEEEQEMFRDFDYIADWC) and phosphatase inhibitor treatment similarly enhanced Thr308 
phosphorylation
(A) Amino acid composition of Akt1 and Akt2 are highly homologous, especially at the 
FxxF C-terminal sequences. Only the active Akt2 crystal structure (PDB code 1o6k) is 
available. Since most of our biochemical studies were performed with Akt1, we indicated 
both Akt1 and Akt2 amino acid residues in the structure for clarity. Superimposition of 
active Akt2 crystal structure (PDB code 1o6k) with active PKA crystal structure (PDB code 
1cdk). Positioning of the Akt C-terminus (colour red) is distinct from the PKA C-terminus 
(colour blue). Whereas Akt C-terminal residues (450–466) are disordered, the PKA C-
terminus stably interacts with its kinase domain through high-affinity contacts. (B) 
Phosphatase inhibitor treatment (100 nM calyculin A) increases Thr308 phosphorylation in 
cytosol-localized Akt (ΔPH-Akt1). PH domain-deleted WT Akt1 (ΔPH-Akt1-WT) was 
transfected into HEK293 cells and exhibits expression localized to the cytosol. After 48 h, 
the transfected cells were propagated for an additional 4 h in exogenous growth factor-free 
medium followed by addition of 100 nM calyculin A for 15 min. Protein extracts were 
subjected to immunoblot analysis using antibodies to phospho-Akt Thr308 and HA tag. (C) 
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Sequence and known Akt-binding affinity values of Akt1 C-terminal tail (19 amino acids), 
phosphomimetic aspartic acid replacement of Ser473 (S473D) tail and PIFtide tail from the 
AGC kinase PRK2 (SEEEQEMFRDFDYIADWC) [37]. The six PIFtide amino acids 
identical with WT Akt sequences are highlighted. The PIFtide sequences were used to 
replace the Akt tail in the cytosolic Akt construct (ΔPH-Akt1-PIF). (D) Cytosolic Akt1 
containing PIFtide (ΔPH-Akt1-PIF) increases Thr308 phosphorylation. ΔPH-Akt1 with 
PIFtide replacement (ΔPH-Akt1-PIF) along with membrane-targeting Myr signal (Myr-
ΔPH-Akt1) and S473D replacement (ΔPH-Akt1-S473D) constructs were transfected into 
HEK293 cells. Transfected cells were incubated for 4 h in medium that was free of 
exogenous growth factors. Protein extracts were subjected to immunoblot analysis using 
antibodies to phospho-Akt Thr308 and anti-HA. The histogram shows the percentage of 
reduced pThr308 phosphorylation from maximally phosphorylated Myr-ΔPH-Akt1. ΔPH-
Akt1-WT (n=7) compared with ΔPH-Akt1-PIF (n=8), *P < 0.001. See Supplementary 
Figure S2C for ΔPH-Akt2-S474D replacement data. (E) ATP binding is required for ΔPH-
Akt1-PIF to enhance Akt phosphorylation. The ATP-binding lysine residue (Lys179 in full-
length human Akt1) was mutated to methionine (K179M) in in ΔPH-Akt1-PIF. HEK293 
cells transfected with indicated constructs were incubated for 4 h in medium free of 
exogenous growth factors, with or without 100 nM calyculin A/2 μM insulin for 30 min.
Chan et al. Page 22
Biochem J. Author manuscript; available in PMC 2015 December 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. PIFtide enhanced Akt phosphatase resistance in cell-free assays
(A) To distinguish heterologously expressed Akt from endogenous Akt, a 41-amino-acid LT 
containing the HA epitope was fused with WT Akt1 (Akt1-LT WT). To define conditions 
that maximally phosphorylate the Thr308 site, Akt1-LT WT was first co-transfected with the 
kinase that phosphorylates the Thr308 site (PDK1). Constitutively phosphorylated Myr-Akt1 
construct was used as positive control. Then, transfected cells were stimulated for 15 min 
with 2 μM insulin plus the tyrosine phosphatase inhibitor pervanadate (Per-VO4) (100 μM). 
Immunoblot analysis using antibodies detecting phosphorylated Akt (Thr308) showed that 
the combined treatment of insulin/pervanadate/PDK1 maximally phosphorylated Akt1-LT 
WT. (B) Akt1 with PIFtide replacement resisted dephosphorylation in cell-free extracts. 
H9C2 cells expressing WT and PIFtide-replaced Akt1-LT constructs were maximally 
phosphorylated by insulin/pervanadate/PDK1 treatment. Flash-frozen cell extracts were 
prepared on ice with phosphatase inhibitor-free detergent extraction buffer. The extracts 
were incubated at 30°C for 30 min. After incubation, protein extracts were subjected to 
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immunoblot analysis using antibodies detecting phosphorylated Akt (Thr308). The histogram 
shows the percentage of Akt dephosphorylation at 0 min and at 30 min (Dephos. %) 
(respectively, Akt1-LT WT, n=5, n=10; Akt1-LT-PIF, n=2, n=4). *P < 0.01 compared with 
Akt1-LT WT at 30 min. (C) Recombinant PIFtide increased phosphatase resistance in 
recombinant WT-Akt. Amino acid position and composition of synthesized peptides used in 
the dephosphorylation assay. Pre-phosphorylated recombinant Akt1 (50 ng) was incubated 
with recombinant PP2A for 10 min or 30 min at 30°C. Assay solution contained 100 μM 
ATP and 10 μM of indicated peptides. Immunoblot images show Akt1 Thr308 
phosphorylation, total Akt1 and PP2A-C protein level. In addition, PIFtide did not affect the 
catalysis of the universal phosphatase substrate, PNPP (Supplementary Figure S2).
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Figure 4. Progressive protection of Akt dephosphorylation by a DDDW targeting groove
(A) Akt structures were superimposed with Akt C-terminal amino acids (purple) or with 
PIFtide amino acids (blue). Image depicts the insertion of PIFtide DW residues into an Akt 
groove. The structure shown is modelled on active human Akt2 crystal structures bound to 
the ATP analogue AMP-PNP and Mn2 + with S474D mutation (PDB code 1o6k) or with 
PIFtide fusion (PDB code 1o6l). Most of our biochemical studies were performed with 
Akt1. When Akt2 structure models were used, we indicate the corresponding Akt1 amino 
acid residues for clarity. (B) The C-terminally modified cytosolic Akt (ΔPH-Akt1) 
constructs were transfected into HEK293 cells and incubated for 4 h in medium that was 
free of exogenous growth factors. Protein extracts were subjected to immunoblot analysis 
using antibodies to phospho-Akt Thr308 and anti-HA. For quantification, we used a two-
colour infrared fluorescence quantitative Western blot system with Li-Cor Odyssey imager 
to measure band intensity from different blots. In each blot, pThr308 signal and the HA 
signal in ΔPH-Akt1-WT were normalized to 1. The specific phosphorylation is the ratio of 
the normalized pThr308 signal to normalized HA signals. *P < 0.001 ΔPH-Akt1-DDW 
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(n=9) or ΔPH-Akt1-DDDW (n=11) compared with ΔPH-Akt1-S473D (n=8). #P < 0.001 
ΔPH-Akt1-DDW compared with ΔPH-Akt1-DDDW.
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Figure 5. C-terminal stabilization in full-length Akt enhances insulin responsiveness
(A) To differentiate from endogenous Akt, a 41-amino-acid LT containing the HA epitope 
was fused with Akt1 (Akt1-LT). C-terminal mutation constructs in Akt1-LT are shown. (B) 
Akt1-LT-DDW and Akt1-LT-DDDW progressively improved insulin sensitivity after 
chronic insulin stimulation (240 min). Indicated Akt1-LT constructs were transfected into 
H9C2 myoblasts and stimulated with 2 μM insulin for 240 min. Protein extracts were 
subjected to immunoblot analysis using antibodies to phospho-Akt Thr308 and anti-HA. (C) 
The graph shows the time course of phospho-Thr308 response after insulin stimulation. 
Quantification shows the pThr308/total Akt ratio after 4 h of insulin stimulation normalized 
to Akt1-LT WT. *P < 0.05 Akt1-LT DDW (n=3) compared with Akt1-LT WT (n=4). (D) 
Unlike phospho-Myr-Akt1, pThr308 in Akt1-LT-DDDW was rapidly dephosphorylated after 
insulin removal. H9C2 cells were pre-stimulated with insulin for 10 min and then insulin 
medium was replaced with serum-free medium and incubated for 60 min. Quantification 
shows pThr308/total Akt ratio after 60 min of insulin removal. (E) DDDW modification 
provided Thr308 dephosphorylation resistance similar to full-length PIFtide in cell-free 
extracts. After maximally phosphorylating both AKT1-LT-WT and AKT1-LT-DDDW by 
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insulin/pervanadate/PDK1 treatment, flash-frozen cell extracts were incubated at 30°C for 
30 min. After incubation, protein extracts were subjected to immunoblot analysis using 
antibodies detecting phosphorylated Akt (Thr308) and HA epitope. The histogram shows the 
percentage of Akt dephosphorylation at 0 min and at 30 min (Dephos. %) (respectively, 
Akt1-LT WT, n=5, n=10; Akt1-LT-DDDW, n=2, n=5). *P < 0.001 compared with Akt1-
LT-WT at 30 min. See also Supplementary Figure S4 for Akt1-LT-PIF compared with 
Akt1-LT-DDDW assay.
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Figure 6. Modified Akt C-terminus confers resistance to ceramide-mediated inhibition
(A) C2-ceramide blocks insulin activation of Akt. H9C2 myoblast cells and primary human 
airway smooth muscle cells were treated for 2 h with 100 μM soluble short-chain ceramide 
(C2-ceramide). Then, cells were stimulated with 2 μM insulin for 30 min. Protein extracts 
were subjected to immunoblot analysis using antibodies detecting phosphorylated Akt 
(Thr308), total Akt and phospho-specific Akt substrate: phospho-PRAS40. GAPDH 
expression was used as loading control. (B) WT and DDDW-modified ΔPH-Akt1 construct 
was transfected into H9C2 myoblasts cells and incubated for 2 h with C2-ceramide before 
insulin stimulation. Immunoblot analysis shows phosphorylated Akt Thr308 levels in both 
transfected ΔPH-Akt1 constructs (45 kDa) and endogenous Akt (60 kDa). The histogram 
shows insulin-stimulated Thr308 phosphorylation in the absence or in the presence of C2-
ceramide (respectively, endogenous WT Akt, n=11, n=16; ΔPH-Akt1-WT, n=4, n=7; ΔPH-
Akt1-DDDW, n=2, n=4). *P < 0.001 compared with endogenous Akt without ceramide. (C) 
Modified Akt C-terminus resisted ceramide treatment. Akt1-LT WT, Akt1-LT-DDW and 
Akt1-LT DDDW constructs were transfected into primary human airway smooth muscle 
cells and were treated for 2 h with 100 μM soluble short-chain ceramide (C2-ceramide). 
Then, cells were stimulated with 2 μM insulin for 15 min. Immunoblot analysis used 
antibodies detecting the HA epitope, phosphorylated Akt (Thr308) and GAPDH loading 
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control. (D) DDDW-modified Akt1 enhanced Akt substrate phosphorylation. Akt1-LT WT 
and Akt1-LT-DDDW constructs were transfected into primary human airway smooth 
muscle cells. Cells were treated with 100 μM C2-ceramide and stimulated with 2 μM 
insulin. Immunoblot analysis used antibodies detecting the HA epitope, phosphorylated Akt 
(Thr308), phospho-specific Akt substrate, phospho-PRAS40 and GAPDH loading control.
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Figure 7. C-terminal stabilization promotes phosphatase-resistance cage formation
After PtdIns(3,4,5)P3 (PIP3 ) binding to Akt PH domain, membrane-bound Akt is 
phosphorylated at the C-terminus (Ser473 in Akt1) and at the activation loop (Thr308 in 
Akt1) by PDK1 and mTORC2 respectively and in a co-ordinated manner. Membrane 
localization also promotes the formation of a phosphatase-resistant cage to shield both 
phosphorylated sites from phosphatases. In the absence of phosphatidylinositol (3,4,5)-
trisphosphate (PIP3 ), cytosolic phosphorylated Akt is dephosphorylated by phosphatases. 
DDDW-modified Akt C-terminus promotes phosphatase resistance at the activation loop.
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